How to Get Retatrutide: Clinical Trials, Access, and Availability

The Short Answer

Retatrutide is not approved by the FDA or any other regulatory authority in the world. It cannot legally be prescribed, dispensed or sold in any country. There are two legitimate ways to receive it: enrolling in an authorized clinical trial sponsored by Eli Lilly, or, since August 2026, Lilly’s single-patient expanded access program. That program is limited to adults with severe, refractory obesity, and a treating physician must make the request.

On July 23, 2026, with the last two pivotal trials reported, Eli Lilly said it planned to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. Its most recent statement (October 8, 2026) is that it plans to file no later than the first quarter of 2027. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA); Lilly is challenging the FDA ruling in court and has not said which pathway it will use. On our estimate, with a 60-day filing review, the earliest realistic approval date is late 2027 with Priority Review, and around the first quarter of 2028 with a standard 10-month review. Commercial supply would follow approval, so the earliest realistic date for a prescription is in 2028.

Until then, a clinical trial or an approved expanded access request is the only way to get pharmaceutical-grade retatrutide under medical supervision.

Current Regulatory Status (October 2026)

Retatrutide (LY3437943) is an investigational triple GIP/GLP-1/glucagon receptor agonist in Phase 3 clinical development. It has no brand name, no approved indication and no marketing authorization anywhere in the world.

Where the TRIUMPH Program Stands

Eli Lilly’s Phase 3 program for retatrutide, called TRIUMPH, is one of the largest metabolic drug programs now underway. It includes several pivotal trials across obesity, type 2 diabetes and metabolic liver disease:

• TRIUMPH-4 was the first trial to report results, releasing top-line data in December 2025. This 68-week study in 445 adults with obesity and knee osteoarthritis showed -28.7% mean weight loss at the 12 mg dose and -26.4% at 9 mg (Eli Lilly press release, December 2025). These are the largest weight loss figures ever reported for any drug in a Phase 3 trial.
• The pivotal program is complete. TRIUMPH-1 (May 21, 2026), TRANSCEND-T2D-1 (March 2026, published in The Lancet in June) and TRIUMPH-2 and TRIUMPH-3 (July 23, 2026) have all reported positive results.
• Eli Lilly plans to file for approval no later than Q1 2027, per its most recent statement (October 8, 2026); its July 23, 2026 statement named obesity, obstructive sleep apnea and knee osteoarthritis pain as the initial indications.

Key TRIUMPH-4 Data Points

TRIUMPH-4 set out retatrutide’s Phase 3 efficacy profile:

• 12 mg dose: -28.7% mean body weight loss at 68 weeks
• 9 mg dose: -26.4% mean body weight loss at 68 weeks
• 99% of participants at 12 mg lost at least 5% of their weight
• 74.3% reduction in knee osteoarthritis pain at 12 mg (75.8% at 9 mg) (WOMAC pain score)
• Dose escalation protocol: 2 mg → 4 mg → 6 mg → 9 mg → 12 mg
• Notable adverse events: dysesthesia (numbness, tingling, burning) in 20.9% at 12 mg and 8.8% at 9 mg versus 0.7% with placebo; nausea in 43.2% and diarrhea in 33.1% at 12 mg

TRIUMPH-4 was the first of five positive pivotal readouts. All five are now in, and the next step is Lilly’s regulatory submission.

Clinical Trial Enrollment: The Main Legitimate Access Pathway

For most people who want retatrutide before it reaches the market, a clinical trial is the only option that gives you a properly made drug under medical supervision with proper safety monitoring.

Active Clinical Trials

These trials are part of the retatrutide Phase 3 program. The four numbered TRIUMPH trials and TRANSCEND-T2D-1 have finished and reported, so enrollment is now limited to the longer-running trials below. Enrollment status changes often, so check the details on ClinicalTrials.gov:

General Eligibility Criteria

Criteria vary by trial, but the TRIUMPH obesity trials generally require:

• Age: Adults 18 years and older (some trials 18-75)
• BMI: ≥30 kg/m2, or ≥27 kg/m2 with at least one weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, or osteoarthritis)
• Exclusion criteria typically include: type 1 diabetes, recent cardiovascular events, bariatric surgery within 12 months, current use of other anti-obesity medications, pregnancy or planning pregnancy, and certain endocrine disorders

For the TRANSCEND diabetes trials, you must have a confirmed diagnosis of type 2 diabetes, an HbA1c within a set range, and stable background diabetes treatment.

How to Explore Trial Enrollment

Start with our Find a Trial page. It is rebuilt from the ClinicalTrials.gov registry on every site update and shows which retatrutide studies still accept participants, their sites by country and US state, and the study contacts.

1. Search ClinicalTrials.gov for “retatrutide” or “LY3437943” to see all registered trials, their status, eligibility criteria and participating sites.
2. Talk to your physician. Your doctor can judge whether you are likely to qualify and refer you to a participating site. A physician referral is often the quickest route to enrollment.
3. Contact study sites directly. Each trial listing on ClinicalTrials.gov gives contact details for recruiting sites. Sites can confirm whether the trial is still enrolling and book a screening visit.
4. Understand the commitment. Taking part in a trial means regular clinic visits (often monthly), the chance of getting placebo instead of the drug, strict visit schedules, lab monitoring, and treatment lasting 68 weeks or longer. Participants also add useful data to what is known about retatrutide.

Important Enrollment Considerations

The pivotal TRIUMPH trials have finished, and most retatrutide trials still running are listed on ClinicalTrials.gov as no longer recruiting. Slots are limited, and access depends on where the sites are.

Taking part in a trial is voluntary, and you can withdraw at any time. Participants get the study drug and medical monitoring at no cost but are not paid for the drug itself.

Expanded Access: A Narrow Second Pathway (Since August 2026)

In August 2026 Eli Lilly confirmed a pre-approval single-patient expanded access program for retatrutide, registered as NCT07629401 with a status of “Available”. Expanded access (sometimes called compassionate use) is an FDA mechanism for supplying an investigational drug outside a trial to a seriously ill patient who has no comparable alternative.

The criteria are strict and all must be met:

• Age 18 or older
• Refractory obesity: BMI 35 kg/m² or higher despite adherence to, and tolerance of, the highest available dose of an approved chronic weight-management therapy
• Two or more serious or life-threatening obesity-related complications currently under standard-of-care treatment
• Unable to participate in an ongoing trial of retatrutide or a comparable investigational drug (because of eligibility criteria or no reasonably accessible site)
• All standard options, including bariatric surgery, discussed with the patient

Requests are made by the treating physician, not the patient, through the Lilly Answers Center at 1-800-LillyRx (1-800-545-5979). Lilly’s record states that availability “will depend on geography, product supply, and detailed individual eligibility assessment”; meeting the criteria does not guarantee supply. Full details, including what the program excludes, are in our expanded access explainer.

When Will Retatrutide Be Available?

This timeline is based on Eli Lilly’s public statements (July 23, August 5 and October 8, 2026) and standard FDA review timelines. All dates are approximate and may change.

Factors That Could Affect This Timeline

• Accelerating factors: Priority Review designation (6-month review instead of 10), a rolling submission, strong safety data across all trials
• Delaying factors: FDA requests for additional data, the unresolved dispute over whether retatrutide is a biologic (which determines the application type), manufacturing scale-up or CMC issues, or an Advisory Committee review

The FDA will look closely at the dysesthesia signal seen in TRIUMPH-4, which affected 20.9% of participants at the 12 mg dose. The later TRIUMPH trials reported lower rates at 12 mg (12.5% in TRIUMPH-1, 7.3% in TRIUMPH-2, 6.4% in TRIUMPH-3), but the signal is still likely to weigh on the review and on labeling decisions.

Compounding Pharmacies: A Legal Gray Area

Compounded GLP-1 drugs have drawn a lot of public attention. The legal position for compounding retatrutide, though, is very different from the one for semaglutide or tirzepatide.

Why Compounded Retatrutide Has No Legal Basis

Under the Federal Food, Drug, and Cosmetic Act, compounding pharmacies may make copies of commercially available drugs in specific circumstances, most notably when the FDA has listed the drug as in shortage. That is how some compounding pharmacies made semaglutide and tirzepatide during documented shortages. The FDA declared those shortages resolved on December 19, 2024 (tirzepatide) and February 21, 2025 (semaglutide).

Retatrutide meets none of these conditions:

• It is not an approved drug. There is no FDA-approved version of retatrutide for a compounding pharmacy to copy.
• It is not in shortage. A drug that is not on the commercial market cannot be in shortage.
• There is no USP monograph or approved reference standard for compounding pharmacies to follow for retatrutide.
• Eli Lilly holds active patents on retatrutide and has shown it is willing to take legal action against unauthorized production of its compounds.

FDA Enforcement Actions

The FDA has become more active in policing compounded GLP-1 products. It has issued warning letters to compounding pharmacies, sought injunctions and worked with state pharmacy boards to enforce compliance. These actions have targeted semaglutide and tirzepatide compounders, but the same principles apply to retatrutide, and more clearly, because there is no shortage exemption to argue.

Any pharmacy claiming to compound retatrutide is working without a recognized legal basis and exposing itself and its customers to regulatory and safety risk.

The Unverified Supplier Problem

Growing interest in retatrutide has brought a wave of online vendors selling products labeled as retatrutide. These products are usually marketed as “research peptides” with disclaimers saying they are “not for human consumption.” The vast majority of these suppliers have no independent quality verification at all.

Why Quality Verification Matters

The core problem is not that research peptide suppliers exist. It is that there are no quality standards. Without independent verification, a buyer cannot know what they are actually getting. The specific risks of unverified products include:

• Unknown purity and identity. Independent analyses of unverified peptide products have repeatedly found wrong compounds, wrong concentrations or large amounts of impurities. Without third-party lab testing and certificates of analysis (COAs) from accredited laboratories, nothing assures you a product contains what it claims.
• No sterility assurance. Injectable products need rigorous sterility testing and manufacturing controls. Suppliers without validated sterility processes risk bacterial contamination, endotoxin contamination and injection site infections.
• Degradation from improper handling. Peptide drugs are sensitive to temperature, light and handling. Without documented cold-chain logistics and stability testing, the product can degrade until it no longer works or forms harmful breakdown products.
• Incorrect concentrations. Without validated assay testing, the actual amount of peptide per vial may differ a lot from the label. That makes accurate dosing impossible.
• No batch traceability. Verified pharmaceutical manufacturing requires full batch records. Without them, quality problems and recalls cannot be traced back to their source.

Why Medical Oversight Matters Regardless of Source

Even a product that contains genuine retatrutide at the right concentration needs medical supervision. The TRIUMPH-4 data show why:

• Dysesthesia occurred in 20.9% of participants at 12 mg and 8.8% at 9 mg (versus 0.7% on placebo). This neurological side effect, which causes numbness, tingling or burning, needs a clinical assessment to rule out other nerve conditions and decide whether the dose should change.
• Gastrointestinal adverse events were common: nausea in 43.2% and diarrhea in 33.1% of participants at the 12 mg dose. Without proper management, these can lead to dehydration, electrolyte imbalances and nutritional deficiencies.
• The dose escalation protocol (2 mg → 4 mg → 6 mg → 9 mg → 12 mg) exists to manage tolerability. Skipping steps or escalating too fast makes adverse events worse.
• Metabolic monitoring is essential for a triple receptor agonist that affects glucose metabolism, lipid metabolism and cardiovascular measures. Hypoglycemia, heart rate changes and effects on the liver need lab assessment.

Regulatory Context

The FDA has issued warning letters to several peptide vendors selling unapproved drug products, including some marketed as GLP-1 receptor agonists. These actions reflect the agency’s view that selling unapproved peptides for human use falls outside the regulatory framework, whatever “research use only” disclaimers say. That makes independent quality verification even more important, because unregulated products are not covered by the manufacturing inspections, batch testing or recall systems that apply to approved medicines.

Approved Alternatives Available Now

If you want effective weight management, you do not need to wait for retatrutide. Several FDA-approved anti-obesity medications are available by prescription today, with well-established safety profiles and proven long-term results:

Currently Approved Options

• Semaglutide (Wegovy): a GLP-1 receptor agonist approved for chronic weight management. Phase 3 trials showed about 15% mean weight loss at 68 weeks. Also approved to reduce cardiovascular risk in adults with obesity (SELECT trial). Weekly subcutaneous injection.
• Tirzepatide (Zepbound): a dual GIP/GLP-1 receptor agonist approved for chronic weight management. Phase 3 SURMOUNT trials showed about 22.5% mean weight loss at the highest dose over 72 weeks. Weekly subcutaneous injection. Also sold as Mounjaro for type 2 diabetes.
• Liraglutide (Saxenda): a GLP-1 receptor agonist approved for chronic weight management. Phase 3 trials showed about 8% mean weight loss. Daily subcutaneous injection.
• Orlistat (Xenical/Alli): a lipase inhibitor that reduces how much dietary fat you absorb. Available by prescription (Xenical) and over the counter (Alli). Modest weight loss of about 3-5%.

Talking to Your Doctor

Your doctor can weigh your medical history, other conditions, contraindications and goals to recommend the best of the currently available options. The weight loss seen with tirzepatide (Zepbound), about 22.5%, is a major advance and may suit many people who might otherwise think about waiting for retatrutide.

If you have type 2 diabetes, both semaglutide (Ozempic) and tirzepatide (Mounjaro) are approved, with strong blood sugar data and cardiovascular benefits.

Weight management also includes behavior change, dietary counseling, physical activity and, in some cases, bariatric surgery. These can be used with or without medication.

Frequently Asked Questions

Can I obtain retatrutide online?

Retatrutide is not approved by any regulatory authority and cannot legally be prescribed or dispensed. Products sold online as “retatrutide” are not made under GMP conditions. Unless independent third-party lab testing has verified them, they carry real risks around purity, sterility, potency and contamination. The FDA has issued warning letters to vendors selling unapproved peptide products. For pharmaceutical-grade retatrutide under medical supervision, the routes are an authorized clinical trial or, for a small number of severely affected patients, Lilly’s expanded access program.

Is retatrutide available in the UK, Europe, or other countries?

No. Retatrutide is not approved or available anywhere in the world as of October 31, 2026. It is an investigational compound in Phase 3 development. Submissions to other regulators (EMA, MHRA and others) are expected to follow the first US FDA filing. European approval would likely come 6-12 months after FDA approval, which puts realistic European availability in 2028-2029 at the earliest.

How do I join a retatrutide clinical trial?

Search ClinicalTrials.gov for “retatrutide” or “LY3437943” to see all registered trials. Each listing gives eligibility criteria, study locations and contact details. Talk to your physician about taking part. They can judge whether you are likely to qualify and refer you. Note that the four numbered TRIUMPH trials have finished. Trials still running as of October 2026 include TRIUMPH-5 (vs tirzepatide), TRANSCEND-T2D-3, several Phase 3b studies and the longer outcomes and liver studies. Most of them are no longer recruiting, so slots are limited.

When will retatrutide receive FDA approval?

Eli Lilly plans to file for approval no later than Q1 2027. On our estimate, assuming the FDA accepts the filing and runs a standard 10-month review, approval could come around the first quarter of 2028; with Priority Review (six months), as early as late 2027. Commercial supply would follow approval, so prescription access is realistically a 2028 event.

Is retatrutide the same as tirzepatide (Mounjaro/Zepbound)?

No. Both are incretin-based peptide drugs developed by Eli Lilly, but they are different molecules that act on different receptors. Tirzepatide is a dual GIP/GLP-1 receptor agonist that is FDA-approved and sold as Mounjaro (type 2 diabetes) and Zepbound (obesity). Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. Its added glucagon receptor activity sets it apart from tirzepatide and may contribute both to its greater weight loss and to its different side effect profile, including the dysesthesia signal.

What is the difference between research peptides and clinical-grade drugs?

The difference is fundamental. Clinical-grade medicines are made under strict Good Manufacturing Practice (GMP) conditions with validated processes. They are tested for identity, purity, potency, sterility and endotoxin content, and overseen by the FDA or an equivalent agency. Every batch is documented, traceable and held to set specifications. “Research peptides” sold online are made without GMP oversight, without regulatory inspection, without validated sterility or potency testing, and without anyone accountable for quality or safety. Independent testing of gray-market peptides has kept finding problems with identity, purity and contamination. For an injectable drug, these differences bear directly on patient safety.

Summary

Retatrutide is not approved or commercially available as of October 31, 2026. The pivotal Phase 3 program is complete. TRIUMPH-1 reported -28.3% mean weight loss at 12 mg over 80 weeks, and TRIUMPH-2 and TRIUMPH-3 confirmed -20.8% and -22.6% in people with diabetes and cardiovascular disease. Eli Lilly plans to file for approval no later than Q1 2027. On our estimate, FDA approval is most likely around the first quarter of 2028 (late 2027 with Priority Review), with commercial supply in 2028. For pharmaceutical-grade retatrutide under medical supervision, the routes are clinical trial enrollment and, for adults with severe refractory obesity, Lilly’s expanded access program. If you are considering other sources, independent quality verification is essential, and as the September 2026 Australian counterfeit case showed, even that cannot rule out a vial that contains a different drug. If you want effective weight management today, ask your healthcare provider about FDA-approved options including semaglutide (Wegovy), tirzepatide (Zepbound) and orforglipron (Foundayo).